7 unchanged lines
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.
Adverse Reactions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
The safety of ENSPRYNG in NMOSD was evaluated in two randomized, placebo-controlled clinical trials [Study 1 evaluated ENSPRYNG without concurrent immunosuppressive therapy (IST) and Study 2 evaluated ENSPRYNG with concurrent IST], which included 41 anti-AQP4 seropositive patients treated with ENSPRYNG in Study 1 and 26 anti-AQP4 seropositive patients treated with ENSPRYNG in Study 2 [see Clinical Studies (14)]. In the double-blind, controlled period, the median exposure time on ENSPRYNG treatment was approximately 2 years in Study 1 and approximately 3 years in Study 2. The median exposure time on placebo treatment was approximately 1 year in both Study 1 and Study 2.
Adverse reactions that occurred in Study 1 and Study 2 in more than 5% of patients treated with ENSPRYNG, and at a greater incidence than in patients who received placebo, are shown in Table 34 and Table 4, respectively5. The most common adverse reactions (15% or greater with ENSPRYNG in either) were nasopharyngitis, headache, upper respiratory tract infection, gastritis, rash, arthralgia, extremity pain, fatigue, and nausea.
Table 34 Adverse Reactions Occurring in 4 or More Patients Treated with ENSPRYNG and Greater Incidence than Placebo in Patients with NMOSD in Study 1
Adverse Reaction | ENSPRYNG (N = 41) % | PLACEBO (N = 23) %
11 unchanged lines
Fall | 10 | 4
Table 45 Adverse Reactions Occurring in 3 or More Patients Treated with ENSPRYNG and Greater Incidence than Placebo in Patients with NMOSD in Study 2
Adverse Reaction | ENSPRYNG + IST (N = 26) % | PLACEBO + IST (N = 26) %
5 unchanged lines
Pharyngitis | 12 | 8
Thyroid Eye Disease (TED)
The safety of ENSPRYNG in TED was evaluated in two phase III randomized, double-masked, placebo-controlled, multicenter clinical trials (Study 3 and Study 4) which included 131 patients treated with ENSPRYNG.
Adverse reactions that occurred in Study 3 and Study 4 in more than 5% of patients treated with ENSPRYNG, and at a greater incidence than in patients who received placebo, are shown in Table 6.
Table 6 Adverse Reactions Occurring in 5% or More of Patients Treated with ENSPRYNG and Greater Incidence than Placebo in Patients with TED (Study 3 and Study 4 Pooled Analysis)
Adverse Reaction | ENSPRYNG (N = 131) % | PLACEBO (N = 124) %
Upper respiratory tract infection | 5.3 | 2.4
Alanine aminotransferase increased | 5.3 | 0.8
Neutropenia was also reported with less than 5% occurrence.
Injection-Related Reactions
NMOSD
In Study 1 and Study 2, injection-related reactions were reported in 9% of patients treated with ENSPRYNG compared with 8% in patients receiving placebo. These reactions in the ENSPRYNG-treated patients were predominantly mild to moderate in severity, and most occurred within 24 hours after the injection. The most commonly reported systemic symptom was diarrhea. The reported local injection site reactions were pruritus, injection site reaction, and skin mass.
TED
In Study 3 and Study 4, injection-related reactions (IRR) were predominantly mild to moderate in severity. No serious IRRs were reported. The most frequently reported systemic symptoms were fatigue and headache, and the most commonly reported local injection site reaction was pruritus. The majority of these events did not require dose interruption or treatment discontinuation, with the exception of two cases (pruritus and injection site reaction) that resulted in the discontinuation of treatment. IRRs were generally self-limiting and resolved without specific treatment.
In an open label trial in healthy adults, in which a single injection of 180 mg/1.5 mL by autoinjector was compared to two injections of 60 mg/0.5 mL and 120 mg/1 mL by prefilled syringe, the most commonly reported local injection site reactions were erythema, edema, induration, and pain. All local injection site reactions were mild to moderate in severity and most were resolved within 24 hours.
Infections
NMOSD
In Study 1, the rate of patients with infections was 51 patients/100 patient-years (95% CI: 32, 78) in patients treated with ENSPRYNG compared with 108 patients/100 patient-years (95% CI: 52, 199) in patients receiving placebo. The rate of patients with serious infections was 5 patients/100 patient-years (95% CI: 1, 14) in patients treated with ENSPRYNG compared with 4 patients/100 patient-years (95% CI: 0, 21) in patients receiving placebo.
In Study 2, the rate of patients with infections was 168 patients/100 patient-years (95% CI: 100, 265) in patients treated with ENSPRYNG compared with 143 patients/100 patient-years (95% CI: 83, 229) in patients treated with placebo. The rate of patients with serious infections was 4 patients/100 patient-years (95% CI: 1, 15) in patients treated with ENSPRYNG compared with 10 patients/100 patient-years (95% CI: 2, 28) in patients receiving placebo.
TED
In Study 3 and Study 4 the rate of infections was lower in patients treated with ENSPRYNG [94.08 events/100 PY (95% CI: 71.07,122.17)] compared with patients receiving placebo [113.92 events/100 PY (95% CI: 86.93,146.64)]. The rate of serious infections was 0.00 events/100 PY (95% CI: 0,6.2) in patients treated with ENSPRYNG compared with 1.90 events/100 PY (95% CI: 0.05,10.58) in patients receiving placebo.
Laboratory Abnormalities
Decreased Neutrophil Count
NMOSD
Of the patients treated with ENSPRYNG, 10% had neutrophils below 1 × 109/L compared to 9% in placebo in Study 1. In Study 2, 15% of patients had neutrophils below 1 × 109/L compared to 4% in placebo. There was one patient in Study 1 treated with ENSPRYNG with neutrophil counts < 0.5 × 109/L, and one patient in Study 2 discontinued ENSPRYNG because of neutropenia.
TED
In Study 3 and Study 4, decreased neutrophil counts through Week 24 were observed in 28.2% of patients treated with ENSPRYNG compared with 9.7% of patients receiving placebo. Of these patients in the ENSPRYNG group, 2.3 % had neutrophil count decreased below 1 x 109/L compared to no patients in the placebo group. The decreased neutrophil counts were not associated with serious infections.
Decreased Platelet Count
NMOSD
In Study 1, a shift in platelet count decreases from normal at baseline to below the lower limit of normal (LLN) occurred in 26% of patients treated with ENSPRYNG compared to 5% of patients receiving placebo. In Study 2, decreases in platelet counts from normal at baseline to below the LLN occurred in 35% of patients treated with ENSPRYNG and in 17% of patients receiving placebo. None of the patients had a decrease in platelet count to less than 50 × 109/L.
TED
In Study 3 and Study 4, decreases in platelet count through Week 24 were reported in 8.4 % of patients treated with ENSPRYNG compared to 2.4% of patients receiving placebo. All decreases in the ENSPRYNG group were characterized by a platelet counts in the range of below the LLN to 75 × 109/L. In the placebo group, two patients experienced decreases in platelet counts to the range of <LLN to 75 × 109/L, and one patient experienced a decrease in platelet count to the range of <75 to 50 × 109/L. None of the patients had a decrease in platelet count to less than 50 × 10⁹/L, and decreases were not associated with bleeding events.
Elevated Liver Enzymes
NMOSD
In Study 1, increases from normal at baseline to above ULN in ALT or AST occurred in 43% and 25% of patients treated with ENSPRYNG, respectively, compared to 13% and 9% of patients receiving placebo. In Study 2, increases from normal at baseline to above the ULN in ALT or AST occurred in 8% and 8% of patients treated with ENSPRYNG, respectively, compared to 12% and 19% of patients receiving placebo.
In Study 1 and Study 2 combined, elevations of ALT or AST greater than 3 times the ULN occurred in 3% of patients treated with ENSPRYNG, compared to no patients treated with placebo. These elevations were not associated with increases in total bilirubin. One patient receiving ENSPRYNG in Study 2 had an elevation of ALT above 5 times the ULN, which was observed 4 weeks after initiation of therapy, normalizing 78 days after discontinuation of ENSPRYNG.
TED
In Study 3 and Study 4, elevations in ALT or AST through Week 24 occurred in 25.2% and 11.5% of patients treated with ENSPRYNG respectively, compared with 7.3% and 4.8% of patients receiving placebo. The majority of elevations were characterized by an elevation above ULN to 3 × ULN. One patient (0.8%) in the placebo group experienced an AST elevation of >3 to 5 × ULN. No transaminase elevations of > 5 to 20× ULN or > 20 × ULN were reported. Most events of ALT and AST elevation resolved without requiring dose modification or discontinuation of ENSPRYNG.
Elevations in ALT or AST were not associated with increase in total bilirubin. Overall post-baseline, liver function tests abnormalities were infrequent, predominantly of low grade and, with no evidence of drug-induced liver injury or hepatotoxicity.
Lipid Abnormalities
NMOSD
In Study 1 and Study 2, elevations in total cholesterol above 7.75 mmol/L (300 mg/dl) occurred in 12% and 15% of patients treated with ENSPRYNG, respectively, compared to no patients receiving placebo.
Elevations in triglycerides above 3.42 mmol/L (300 mg/dl) occurred in 27% and 12% of patients treated with ENSPRYNG in Study 1 and Study 2, respectively, compared to 13% and 8% of patients receiving placebo.
TED
In Study 3 and Study 4, increases in total cholesterol through Week 24 were reported in 19.8% of patients treated with ENSPRYNG compared with 9.7% of patients receiving placebo. Elevations in cholesterol above 7.75 mmol/L were observed in 9.2% of these patients treated with ENSPRYNG compared with 2.4% of corresponding patients receiving placebo.
Increases in triglycerides were through Week 24 reported in 33.6% of patients treated with ENSPRYNG compared with 27.4 % of patients receiving placebo. Elevations in triglycerides above 3.42 mmol/L were observed in 1.5% of patients treated with ENSPRYNG compared with 3.2% of patients receiving placebo. The elevations in lipid parameters did not require treatment discontinuation
Fibrinogen Levels
NMOSD
In Study 1, the median percent reduction in fibrinogen was 38% in patients treated with ENSPRYNG compared to 5% in patients receiving placebo. In Study 2, the median percent reduction in fibrinogen level was 33% in patients treated with ENSPRYNG compared to 0% in patients receiving placebo.
Complement Levels
NMOSD
In Study 1, the median percent reduction in the C3 and C4 components of complement was 23% and 50% in patients treated with ENSPRYNG, respectively, compared to 0% and 1% patients receiving placebo. In Study 2, the median percent reduction in the C3 and C4 components of complement was 20% and 53% in patients treated with ENSPRYNG, respectively, compared to 0% and 1% in patients receiving placebo.
Body Weight
NMOSD
In the pool of Studies 1 and 2, body weight increases of at least 7% from baseline occurred in 28% of patients treated with ENSPRYNG compared to 8% of patients receiving placebo.
2 unchanged lines
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of anti-satralizumab-mwge antibodies in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.
In NMOSD Study 1 and NMOSD Study 2, anti-drug-antibodies (ADAs) were observed in 73% and 38% of patients receiving ENSPRYNG in the double-blind period, respectively. The ability of these ADAs to neutralize satralizumab-mwge binding is unknown. Patients with higher body weight and lower exposure were more likely to develop ADAs (irrespective of treatment with IST). Exposure was lower in ADA positive patients. Although anti-satralizumab-mwge antibody development was not found to affect the efficacy of ENSPRYNG in these patients, the available data are too limited to make definitive conclusions. Immunogenicity does not have a clinically-relevant impact on safety. Based on the available information, neither dose interruption nor modification is warranted in those patients who develop ADAs.
In TED Study 3 and TED Study 4, anti-drug-antibodies (ADAs) were observed in 44.8% and 39.1% of patients receiving ENSPRYNG, respectively. The ability of these ADAs to neutralize satralizumab-mwge binding is unknown. ADA incidence is similar in the 120 mg (50 of 119, 42%) and 180 mg (5 of 12, 41.7%) dose groups. Exposure was lower in ADA positive patients. Immunogenicity does not appear to have a clinically-relevant impact on safety, efficacy or PD.